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Abstract The prevalence of relevant oncogenic drivers in lung adenocarcinoma varies in our region and
 data on clinical outcomes is scarce. The objective of the study was to describe the prevalence of 
KRAS, BRAF and EGFR mutations and ALK translocations in patients with advanced lung adenocarcinoma, and 
to depict the clinical outcome according to treatment strategies. Patients with adequate tumor biopsy sampling 
were included. KRAS, BRAF and EGFR mutations were studied by Sanger sequencing. ALK translocations were 
studied by fluorescent in situ hybridization (FISH) and immunohistochemistry (IH) with antibodies against ALK 
with clones D5F3 and 5A4. Informed consent was signed by 118 patients and 84 (72%) with complete molecular 
analysis were included. KRAS mutations were detected in 16 samples (19%), EGFR in 11 (13%), 9 of them 
conferring sensitivity to EGFR inhibitors, and BRAF mutations in 1 (1%). ALK translocations were detected in 3 
samples (4%). Median follow-up was 42.4 [interquartile range (IQR): 27.0-64.2] months. Globally, median overall 
survival was 10.3 [IQR: 5.6-20.2] months. Median survival was 10.8 [IQR: 6.0-20.3] months in the group of pa-
tients without detectable molecular alteration, 9.6 [IQR: 3.7-16.1] months in KRAS mutant population (HR: 1.08; 
p = 0.82) and 32.5 [IQR: 19.6-38.4] months in patients with ALK translocations or sensitizing EGFR mutated 
tumors treated with tyrosine kinase inhibitors (HR: 0.27; p = 0.03). In conclusion, the prevalence of molecular 
alterations and outcomes in our population is similar to that reported in other studies in Western countries. 
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Resumen Distribución de subtipos moleculares de adenocarcinoma de pulmón y resultados clínicos en
 un centro de Argentina. La prevalencia de alteraciones en oncogenes en adenocarcinoma de 
pulmón varía en nuestra región. El objetivo fue describir la prevalencia de mutaciones en KRAS, BRAF y EGFR 
y las translocaciones de ALK en pacientes con adenocarcinoma de pulmón y estudiar la supervivencia de 
acuerdo a subtipos moleculares. Se incluyeron pacientes con biopsias adecuadas para el estudio. Se evaluó el 
estado mutacional de KRAS, BRAF y EGFR  por secuenciación con la técnica de Sanger. Las translocaciones 
de ALK se estudiaron por hibridación in situ por fluorescencia (FISH) e inmunohistoquimica (IHQ) contra ALK 
(clones D5F3 y 5A4). De 118 pacientes evaluados, se incluyeron 84 (72%) con análisis molecular completo. 
Se detectaron mutaciones de KRAS en 16 muestras (19%), EGFR  en 11 (13%), y BRAF en 1 muestra (1%). 
Se detectaron rearreglos de ALK en 3 muestras (4%). La mediana de seguimiento de los pacientes fue de 42.4 
[rango intercuatilo (RIC): 27.0-64.2] meses. Globalmente, la mediana de supervivencia en la población fue 10.3 
[RIC: 5.6-20.2] meses y fue de 10.8 [RIC: 6.0 20.3] meses en pacientes sin alteraciones moleculares detecta-
bles. La mediana de supervivencia de los pacientes con mutación en KRAS fue de 9.6 [RIC: 3.7-16.1] meses 
(HR: 1.08; p  =  0.82) y 32.5 [RIC: 19.6-38.4] meses en el grupo con rearreglos de ALK o mutaciones en EGFR 
tratados con inhibidores de tirosina quinasa (HR: 0.27; p  =  0.03). En conclusión, la prevalencia de alteraciones 
moleculares en nuestra población fue similar a otros países occidentales. 
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Lung cancer is the first cause of cancer-related deaths 
in the world. In Argentina, by the year 2018, lung cancer 
accounted for 10 662 estimated deaths, being the first in 
cancer mortality among men1. Mortality has been increas-
ing among females and decreasing among males in the 
last decade. Worldwide, only 15% of patients remain alive 
at 5 years, mainly because around 70% of lung cancers 
present at advanced stages. Non-small cell lung cancer 
(NSCLC) accounts for 85% of cases, with lung adenocar-
cinoma being the most common histology2.  
For decades, chemotherapy was the sole treatment 
for metastatic lung adenocarcinoma until the develop-
ment of targeted therapies against driver oncogenes 
and the emerging role of immunotherapy. Over 60% 
of lung adenocarcinomas harbor a genomic mutation, 
amplification or translocation in key cell signaling path-
ways3-7. Many of them can be targeted with actionable 
drugs8, 9.The V-Ki-ras2 Kirsten rat sarcoma viral onco-
gene homolog (KRAS) mutations accounted for 32% of 
cases in The Cancer Genome Atlas (TCGA), with no 
effective therapy against this mutation5. The epidermal 
growth factor receptor mutations (EGFR) occur in 11% 
to 15% in Western countries, and sensitizing mutations 
predict responses with EGFR inhibitors in around 70% of 
patients10-15. Erlotinib, gefitinib and afatinib are approved 
EGFR tyrosine kinase inhibitors (TKI) currently available 
for first line therapy in the metastatic setting. Osimertinib 
is a third generation EGFR inhibitor with proven efficacy 
in reverting treatment resistance when the T790M sec-
ondary mutation is present16.
Anaplastic lymphoma kinase (ALK) rearrangements 
occur in 3% to 5% of lung adenocarcinomas and con-
fer sensitivity to ALK inhibitors like crizotinib, ceritinib, 
alectinib, brigatinib and lorlatinib5, 9, 17-21. As for EGFR 
inhibitors, second and third generation ALK inhibitors can 
potentially revert acquired resistance and have enhanced 
central nervous system penetration22, 23. Dabrafenib and 
trametinib, BRAF and MEK inhibitors respectively, have 
shown activity in patients with BRAF V600E mutant lung 
cancers24. 
The distributions of these molecular alterations vary 
according to race and, consequently, geographical local-
ization. Approximately 30-50% of Asian patients with lung 
adenocarcinoma harbor EGFR mutations compared to 
11% in the Caucasian population25. There are no signifi-
cant differences in ALK rearrangements between Asian 
and Caucasian populations26.
In Latin America, the largest analysis of 5738 lung cancer 
patients reported variable results in the prevalence of EGFR 
mutations ranging from 14% in Argentina, 25% in Colombia, 
27% in Panama, 31% in Costa Rica, 34% in Mexico to 51% 
in Peru27. The largest series in Brazil shows a 25% to 30% 
prevalence of EGFR mutations28, 29. The frequency of KRAS 
mutations in Latin-American population is around 14%, as 
evidenced by data from México, Colombia and Peru, and 
Brazil27, 29.There are no data available on the prevalence 
of KRAS and BRAF mutations in lung cancer in Argentina.
This study reports the prevalence of somatic mutations 
in EGFR, KRAS, BRAF and ALK translocation in consecu-
tive patients with advanced stage lung adenocarcinoma in 
a prospective population at a single institution in Argentina. 
The treatments and survival of the patients in this cohort 
are also described. 
Materials and methods
Consecutive patients with newly diagnosed stage IIIB or IV 
lung adenocarcinoma or disease relapse after surgery were 
eligible to participate in the study. Eligible patients were over 
18 years of age, had an Eastern Cooperative Group (ECOG) 
performance status ranging from 0 to 2, and tissue sample 
available for complete molecular analysis. Patients were ex-
cluded from the study in the case of inadequate tissue sample 
for complete analysis or different histopathological diagnosis 
on biopsy revision. 
This is a descriptive prospective study carried out at a 
single academic institution in the city of Buenos Aires. Patients 
were enrolled from March 2012 to December 2014 and were 
followed until their death, withdrawal of informed consent or 
study cut-off on February 20th, 2016. The primary endpoint 
of the study was to determine the prevalence of mutations in 
EGFR, KRAS and BRAF, as well as ALK translocations. The 
secondary endpoints were to describe patient’s characteristics, 
treatment strategies and clinical outcomes according to the 
tumor molecular subtype and compare the yield of surgical 
and non-surgical biopsies (endoscopic or percutaneous image-
guided) for complete molecular analysis. The attending physi-
cian selected patient treatments based on molecular biology 
status and the standard treatments approved in Argentina.  
The protocol was reviewed and approved by the institution 
ethics committee and was conducted in accordance with the 
Declaration of Helsinki and the Good Clinical Practice protocol 
requirements. All patients signed an informed consent form to 
participate in the study. 
Histopathology diagnosis: formalin-fixed paraffin-embedded 
tissue (FFPET) samples were cut in 3-4µm sections and 
stained with hematoxylin and eosin for morphological analysis. 
Additional complementary immunohistochemistry assays were 
performed when necessary for diagnostic purposes, and tumor 
histology was defined by the World Health Organization (WHO) 
classification of lung cancer30. All samples were reviewed to 
confirm adenocarcinoma histology.
Molecular biology: DNA was purified from FFPET samples 
with a minimum of 70% of tumor cells selected by tissue mi-
crodissection. Paraffin was removed with xilol-ethanol 100% 
and DNA was purified with QIAamp® DNA FFPET (Qiagen, 
Germany). Purity and yield were measured with spectropho-
tometry. PCR amplification was performed with intronic primers 
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for KRAS exon 2, EGFR exons 18 to 21 and BRAF exons 
11 and 15 (Table 1). All PCR products were evaluated by 
electrophoresis with agarose gel 2% in TBE 1X solution with 
ethidium bromide, and were analyzed under UV light. Sanger 
sequencing was done with BigDye Terminator v3.1 Cycle 
Sequencing Kit (Applied Biosystems, USA). The sequences 
were separated by capillary electrophoresis in ABI PRISM 
310 Genetic analyzer (Applied Biosystem, USA) and analyzed 
with Sequencing Analysis Software v5.2 (Applied Biosystem, 
Foster City, CA, USA).
ALK determination was done by immunohistochemistry 
(IHC) and fluorescent in situ hybridization (FISH): ALK fusions 
were tested by FISH with Vysis ALK Break Apart Probe kit 
(2p23/ALK translocation detection, Abbott, USA), IHC with ALK 
Testing (clone D5F3, Ventana-Roche, CE-IVD) and manual 
IHC with monoclonal antibody 5A4 (ab17127, ABCAM-Inc. 
Cambridge, MA. USA).
 FFPE FISH tissue samples were processed in 4-5 mi-
cron sections. Enzymatic digestion was performed with Vysis 
Paraffin Pretreatment IV. The Food and Drug Administration 
(FDA) approved Vysis ALK Break Apart Probe kit (2p23/ALK 
translocation detection, Abbott, USA) was used. A positive test 
was considered when green and red signals were separated 
by >2 signal diameters in over 15% of cells. 
ALK testing (Ventana-Roche, CE-IVD): FDA approved 
IHC kit with rabbit monoclonal antibody (clone D5F3) in com-
bination with OptiView DAB IHC Detection kit and OptiView 
Amplification Kit. This IHC was done with BenchMark® GX-
Ventana-Roche platform. The high sensitivity and specificity 
of this method admits a binary interpretation, being positive 
with an intense cytoplasmic granular stain. 
Manual IHC (clone 5A4): FFPET 3-4µm sections underwent 
dehydration and endogenous peroxidase blocking, and were 
incubated for 2 hours in an IHC-humidity-chamber with primary 
ALK monoclonal antibody clone 5A4 (ab17127, ABCAM-Inc. 
Cambridge, MA. USA). The revealing process was made with 
3,3’-diaminobenzidine (DAB) chromogen. A semi-quantitative 
score was established to assess this method: 0 score was 
absence of staining, 1+ weak cytoplasm staining < 10%, 2+ 
moderate staining, and 3+ intense and granular staining, the 
later considered as positive.
For descriptive statistics, variables were grouped and cate-
gorized as continued or categorical. Continuous variables were 
summarized with median (p50) and interquartile range (p25-
p75). Categorical variables were presented as proportions. 
Overall survival was calculated from the time of diagnosis of 
stage IIIB or metastatic disease until death or study termina-
tion. Survival analyses were estimated with Kaplan-Meier, and 
the comparison between groups was evaluated with Wilcoxon 
rank-sum (Mann-Whitney) test. Median follow-up time was 
estimated with the reverse Kaplan-Meier method. The yield 
of surgical and non-surgical (endoscopic or percutaneous) bi-
opsies for molecular analysis was assessed by comparing the 
proportion of complete, incomplete and absence of molecular 
analysis between procedure types using the Fisher exact test. 
Results
From March 2012 to December 2014, 118 consecutive 
patients signed the informed consent. Two individuals 
with an alternative diagnosis on pathology revision were 
excluded from the study, one with diagnosis of pleural 
mesothelioma and one with squamous NSCLC. From 
116 individuals with lung adenocarcinoma histology, 32 
(28%) had tumor biopsies with inadequate or insufficient 
tissue for complete analysis: 21 had incomplete molecular/
TABLE 1.– Primer sequences, annealing temperature (°C), amplicon size (bp) for hotspot sequencing of candidate genes
Gene Exon Primer 5’-3’ °C Bp Hot Spot 
KRAS 2 Forward GGCCTGCTGAAAATGACTGAA 60 163 G12V/D/S/A/C/R - G13D
  Reverse GGTCCTGCACCAGTAATATGC    - V14X - G15X
EGFR 18 Forward CAGCATGGTGAGGGCTGAGGT 66 186 G719C/S/A - V869M - 
  Reverse GGCCTGTGCCAGGGACCTTAC   N700D - E709K/Q - 
       S720P (#)
 19 Forward GCACCATCTCACAATTGCCAGTTA 63 207 Deletion (E746-P753  
  Reverse AAAAGGTGGGCCTGAGGTTCA   region) - D761Y (#)
 20 Forward CGAAGCCACACTGACGTGCCT 66 201 T790M - insertion (D770-
  Reverse AGTTGAGCAGGTACTGGGAGCCA   N771 region) - V769L -
      S768I - V765A - T783A (#)
 21 Forward CCTCACAGCAGGGTCTTCTCTGT 66 222 L858R - N826S - A839T -
  Reverse TCAGGAAAATGCTGGCTGACCTA   K846R - L861Q - G863D (#)
BRAF 11 Forward TCCCTCTCAGGCATAAGGTAA 58 313 G466E/V - G469A
  Reverse CGAACAGTGAATATTTCCTTTGAT  
 15 Forward TCATAATGCTTGCTCTGATAGGA 58 224 V600E/D/K/R - D594V/G - 
  Reverse GGCCAAAAATTTAATCAGTGGA   K601E
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Patients with stage IIIB/IV lung 
adenocarcinoma  that signed inform 
consent n=118
Excluded n=34
 Alternative diagnosis on pathology 
review n=2 
• Incomplete or no molecular analysis 
n=32 
Patients included with complete molecular 





• Sensitizing to EGFR 
inhibitors n=9









Fig. 1.– Patients and samples workflow
IHC profiling and 11 samples were not suitable for any 
molecular/IHC technique. Therefore, 84 individuals (72%) 
with complete molecular profiling in the tumor sample were 
included in the analysis. (Fig. 1)
Lung biopsies were the most frequently studied 
(n = 63), followed by lymph nodes (n = 25), bone (n = 13), 
brain (n = 7), liver (n = 4), adrenal gland (n = 2), kidney 
(n = 1) and soft tissue metastasis (n = 1). From 116 
biopsies with diagnosis of lung adenocarcinomas evalu-
ated for IHC/molecular analysis, 71 (61.2%) were surgical 
biopsies, 34 (29.3%) were percutaneous image-guided 
biopsies and 11 (9.5%) were endoscopic biopsies. The 
yield of surgical biopsies for complete molecular analysis 
was significantly higher compared to non-surgical biop-
sies, 87% versus 49% (p = 0.0001). Around 20% of non-
surgical biopsies were not suitable for molecular analysis 
compared to 3% of surgical biopsies (Fig. 2).  
The median age for patients with complete molecular 
analysis was 64 years [IQR: 58-71] and 55% were men. A 
total of 54 patients (64%) presented with upfront metastatic 
disease and 30 (36%) had disease relapse after initial cura-
tive intent: stage I (n = 15), stage II (n = 8), and stage III 
disease (n = 7). With regard to smoking habits, 40 patients 
(48%) were former smokers, 28 (33%) were current smok-
ers and 16 (19%) were never smokers. ECOG performance 
status score was 0 or 1 in 84% of individuals and 18% had 
experienced greater than 10% of weight loss at diagnosis. 
The most common sites of metastasis were the bones, 
lymph nodes, lungs and central nervous system (Table 2). 
A genetic alteration was reported in 37% of analyzed 
tumor samples: KRAS mutations were detected in 16 
samples (19%), EGFR mutations in 11 samples (13%), 
ALK rearrangements in 3 samples (4%) and a BRAF 
mutation in 1 sample (1%). No molecular alterations were 
detected in 52 samples (53%) (Fig. 3). 
The following mutations were detected in KRAS: 
G12C (n = 5), G12D (n = 3), G12V (n = 3), G13S (n = 3), 
G13B (n = 2) and G13C (n = 1). One sample harbored 
a KRAS G12C and G13S co-mutation. In samples with 
EGFR mutations, 9 had mutations predicting benefit to 
treatment with EGFR TKI: exon 19 deletions (n = 5), 
L858R in exon 21 (n = 3), E709K in exon 18 (n = 1). 
Two samples harbored exon 20 insertions (D770_N771 
and V774_C775), associated with primary resistance to 
treatment with EGFR TKI. 
ALK rearrangement were detected by FISH and ALK 
IHC with clone D5F3 in 3 samples (4%). We observed 
an IHC false negative result in one case with clone 5A4 
(score 1+). One sample (1%) had a BRAF G469A muta-
tion in exon 11. This mutation is associated with lack of 
response to BRAF inhibitors. We did not detect BRAF 
V600E mutations.  
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Fig. 2.– Yield of biopsy sampling method for molecular analysis
Globally, 71 patients (84%) received at least one line of 
systemic therapy for advanced disease: 43 (51%) received 
one, 18 (21%) two lines, 8 (10%) three lines and 2 (2%) 
received 4 lines of therapy. Carboplatin or cisplatin plus 
pemetrexed was the preferred first line regimen (77%). 
Other first line treatments were platinum-based combina-
tions of paclitaxel or pemetrexed with bevacizumab (8%), 
and carboplatin given concomitantly with taxanes (6%).  
In patients with non-detectable alterations (n = 53) and 
KRAS mutant tumors (n = 16), 46 (87%) and 15 (94%) 
received chemotherapy, respectively. Seven patients did 
not receive chemotherapy treatment because of clinical 
deterioration and poor performance status. In the group 
of patients with EGFR mutations (n = 11), three did not 
meet clinical criteria for treatment with TKI due to the 
presence of EGFR TKI resistant exon 20 insertions (n = 2) 
and surgical resection of a single brain metastasis in a 
patient without evidence of extracranial disease (n = 1). 
Among 8 patients with clinical indication of treatment with 
EGFR TKI, 3 received treatment with erlotinib, one with 
gefitinib and one with afatinib. Among patients with ALK 
translocation, one received ALK TKI crizotinib and the 
remaining received chemotherapy. Reasons for not receiv-
ing EGFR/ALK inhibitors were: rapid clinical deterioration 
(n = 3), lack of access to TKI by insurance delay (n = 1) 
and false negative testing with ALK 5A4 antibody (n = 1). 
The median duration of follow-up for individuals in-
cluded in the analysis was 42.4 months [IQR: 27.0-64.2]. 
At study completion, 71 patients had died (85%). Median 
overall survival for the whole population (n  =  84) was 
10.3 months [IQR: 5.6-20.2]. In the group of patients with 
tumors that did not have detectable molecular alterations, 
median overall survival was 10.8 months [IQR: 6.0-20.3]. 
Patients with KRAS mutated tumors had a median overall 
survival of 9.6 [IQR: 3.7-16.1] months (HR 1.08, 95% CI 
0.55-2.12; p = 0.82). 
In patients receiving at least one line of systemic ther-
apy (n = 67), the median overall survival for the group of 
patients without detectable molecular alterations (n = 46) 
was 13.65 months [IQR: 6.4-20.0] (Fig. 4). In the KRAS 
mutant subgroup, the median overall survival of patients 
receiving systemic treatment (n = 15) was 10.3 [IQR: 3.7- 
16.8] months (HR: 1.08, 95% CI 0.54-2.18; p = 0.80). In 
patients with EGFR mutant and ALK rearranged tumors 
treated with TKI (n = 6), the median overall survival was 
32.5 [IQR: 19.6 – 38.4] months (HR: 0.27, 95% IC 0.08 
– 0.9, p = 0.033). 
Discussion
The understanding of the local prevalence of molecular 
alterations in patients with lung adenocarcinoma is rel-
evant to optimize their cancer care. In this study, around 
14% of patients had an actionable EGFR mutation or ALK 
fusion, rendering further opportunities of treatment with 
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tyrosine kinase inhibitors. The prevalence of EGFR and 
ALK mutations in this study was similar to that reported 
previously in other series from Argentina27, 31. Interestingly, 
the prevalence of EGFR mutations seems lower compared 
to other countries in Latin-America27. To our knowledge, 
this is the first study to report results of KRAS mutations 
in Argentinean population, The prevalence of KRAS mu-
tations in our population were similar to the reported in 
Mexico, Colombia, Peru and Brazil and lower compared to 
TCGA and French cohorts27, 29. The prevalence of EGFR 
mutations and ALK rearrangements in our population 
was similar to that reported in studies from other western 
countries in Europe and North America9, 32. 
The study of targetable molecular drivers allows to 
optimize patients care by providing personalized cancer 
therapies. In our study, patients whose tumors harbored 
TABLE 2.– Clinical characteristics of patients with complete molecular analysis
Characteristics N° of patients %
Age at diagnosis (median) 64 [IQR: 57.7 - 71]  
Sex   
   Men 46 55
   Women 38 45
Ethnicity
    Caucasian  78 93
    Native American 5 6
    Asian 1 1
Disease presentation
   Upfront advanced disease 54 64
   Relapsed disease at inclusion 30 36
Smoking habit  
    Current 28 33
    Former 40 48
    Never 16 19
PS ECOG   
   0 35 42
   1 35 42
   2 14 16
Weight loss > 10% 15 18
Stage at inclusion  
  IIIB 11 13
   IV 73 87
Number of metastasis sites  
   1 56 67
   2 19 23
   3 or more 9 11
Site of metastasis 
Bone 32 38





Adrenal gland 6 7
Kidney 1 1
Peritoneum 1 1
PS ECOG: Performance status according to the Eastern Cooperative Oncology Group scoring system; 
CNS: Central nervous system
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most common diagnostic procedures. In this initial study, 
around 50% of non-surgical biopsies were insufficient for 
a complete KRAS, EGFR, BRAF and ALK tumor profiling. 
In addition to these biomarkers, current clinical standard 
practice requires testing for programmed death-ligand 1 
(PD-L1) expression by IHC, and ROS1 fusions by FISH 
demanding the use of additional tissue. With the use of real 
time PCR and next generation sequencing, the required 
total amount of DNA needed per sample is diminishing, 
increasing the efficiency of molecular diagnostics. How-
ever, PCR and Sanger sequencing remain the available 
methodology in many laboratories.  These observations 
are relevant to establish the quality and size of tumor 
samples and to improve multidisciplinary diagnostic strate-
gies in each institution37. 
Our study has limitations, it is a single institution study 
from an academic hospital in the city of Buenos Aires, 
therefore we cannot extrapolate the prevalence of mo-
lecular alterations to the entire country. In addition, the 
small sample and the relative low proportion of patients 
with EGFR/ALK alterations treated with kinase inhibitors 
may overestimate the magnitude of the benefit of this 
strategy in our cohort. 
Fig. 3.– Distribution of molecular subtypes in tumor samples with complete 
analysis (n=84)
targetable molecular drivers experienced prolonged sur-
vival when treated with kinase inhibitors, in accordance 
with clinical studies with first line EGFR and ALK inhibi-
tors33. The overall survival of patients with EGFR mutant 
lung cancer treated upfront with gefitinib, in the phase 
III study with the longest follow up, was 34.834. Also, 
impressive long-term survival can be achieved with ALK 
inhibitors, with a 4-year survival rate of 56.6% for patients 
treated upfront with crizotinib in the PROFILE 1014 trial35. 
We also observed that patients without detectable drivers 
treated with chemotherapy had had similar survival out-
comes to those reported for patients treated with platinum-
pemetrexed and maintenance therapy (~ 13 months) in 
phase III clinical trials36.
Adequate tissue sampling and processing are crucial 
to perform multiple techniques required for accurate 
histological diagnosis and molecular profiling of limited 
tumor tissue. In this study, we performed multiple DNA 
based PCR amplifications, FISH and IHC techniques on 
limited biopsy material. Surgical samples conferred a 
higher rate of success for complete molecular profiling 
compared to non-surgical biopsies. However, in clinical 
practice, percutaneous and endoscopic samples are the 
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To our knowledge, this study is the first study in our 
population to report the prevalence of EGFR, KRAS and 
BRAF mutations together with ALK translocations, and 
to study the patient’s characteristics and outcomes ac-
cording to molecular subtype and therapeutic strategy in 
our country. 
In conclusion, the prevalence of EGFR, KRAS and 
BRAF mutations and ALK translocations observed in 
this single center study is comparable to that reported in 
western countries. Patients whose tumors harbor EGFR 
sensitizing mutations and ALK translocation have a longer 
survival when treated with targeted therapies. The study 
of multiple genes is feasible and demands optimization 
of tumor sampling. 
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LA TAPA
Passionaria caerulea, L. 1753
Sello postal de Argentina, 2009
Sello postal, Serie Fauna y Flora. Especies nativas, 2009. Diseño Magdalena Pérez del Cerro. Fotografía Nilce 
Silvana Enrietti. Imprenta Letra Viva, Buenos Aires. Volante Filatélico Nro. 1139. Correo Argentino. Jalil GA., Göttig 
JL. Catálogo Especializado de Sellos Postales de la República Argentina. 1856-2010. N° 3746. Sello y fotografía Dr. 
Claudio Zuckerberg. Digitalización BB.
Flor de Passiflora caerulea, L. 1753 (pasionaria azul, flor de la pasión,  mbucuruyá, granadilla). La pasionaria es 
una planta enredadera, nativa de Sudamérica. Crece espontáneamente o cultivada. La flor, por sus características, 
está asociada a imaginativas leyendas y a la simbología cristiana de la pasión de Jesús: los estilos representan los 
tres clavos usados para clavarlo, las cinco anteras las cinco heridas; la corola la corona de espinas, los zarcillos 
el látigo con que fue flagelado, etc. Los frutos se han incorporado a la gastronomía por sus “maravillosos” benefi-
cios, según los que patrocinan su consumo. A las infusiones de flores, hojas y corteza de las ramas se le atribuyen 
propiedades medicinales: ansiolíticas, sedantes, antiespasmódicas, somníferas, y muchas más. Hay preparaciones 
farmacéuticas de venta libre en la forma de extractos, líquidos, comprimidos y jarabes. En estos sedantes “naturales” 
se combinan los extractos de pasionaria con los de valeriana, tilo, espino (Crataegus), sauce, y, en alguno, vitamina 
B1. El lector interesado encuentra en PubMed, el 7/10/2018: passion flower, 659 referencias, y en passion fruit, 747. 
Y hay un misterio en la historia del arte: ¿Quién y cuándo agregó la pasionaria en un cuadro de Joos van Cleve (c. 
1485-1540) datado 1530-35. En Europa, en los años 1530-35, no se conocía ni la flor real o en un herbario, ni una 
descripción escrita o una imagen.
(Michel E. Abrams en: 
1. www.flwildflowers.com/vancleve/. 2. www.flwildflowers.com/clues/).
